Anaphore scoops up Chinese biotech; Clovis reveals $75M offering;

 @FierceBiotech: Researchers at the University of Bonn coaxed immature brain stem cells from mouse connective tissue. Story | Follow @FierceBiotech

 @JohnCFierce: Interesting piece from @reutersBenHir assessing all the problems with depression drugs. More | Follow @JohnCFierce

 @RyanMFierce: Who likes Durata Therapeutics' chances of pulling off an IPO? Release | Follow @RyanMFierce

@MarkHFierce: So there might be a genetic reason for chronic diarrhea, via MedPageToday. Story | Follow @MarkHFierce

> La Jolla, CA-based biotech Anaphore said that it has acquired Shanghai-based RuiTi, which specializes in discovering biologics that target G-protein coupled receptors. Release

> Boulder, CO-based cancer drug developer Clovis Oncology ($CLVS) has announced plans for a $75 million public offering. Report

> Paris-based Enterome, which specializes in biomarker discovery, has raised $6.6 million in a Series A round of funding. Report

Pharma News

 @FiercePharma: Shire chairman took home £8.5m. Article via @Guardian | Follow @FiercePharma

> Meet the new publisher of FiercePharma. More

> FDA seeks advice on making more drugs OTC. Story

> GlaxoSmithKline undeterred by spotty results for Relovair. Item

> EMA OKs Byetta for expanded treatment. News

> British Medical Journal focuses on questionable patent extension. Article

And Finally… Struggling AstraZeneca ($AZN) might be in the market to acquire U.S. drugmaker Forest Laboratories ($FRX). Item

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.